Date: 3/18/2008
LIGOCYTE PHARMACEUTICALS FINALIZES AGREEMENT FOR $28M SERIES “C” FINANCING ROUND
SOURCE: LigoCyte Pharmaceuticals, Inc.
Bozeman, MT – March 18, 2008 – LigoCyte Pharmaceuticals, Inc., a vaccine company in Bozeman, Montana, announced that the company has successfully finalized an agreement for a $28 million venture capital financing round to further clinical development of its two lead vaccines against norovirus and influenza. Read More

Date: 9/18/2007
LIGOCYTE PHARMACEUTICALS ANNOUNCES COLLABORATION WITH BIOGEN IDEC TO DEVELOP ANTI-CD103 THERAPIES
SOURCE: LigoCyte Pharmaceuticals, Inc.
Bozeman, MT – September 18, 2007 – LigoCyte Pharmaceuticals, Inc., today announced a strategic partnership with Biogen Idec (NASDAQ: BIIB) to develop therapies targeting CD103 for the treatment of chronic inflammatory diseases including potential respiratory, gastrointestinal, and autoimmune indications. CD103 is the unique alphaE-beta7 integrin that has been implicated in the activation, homing and retention of lymphocytes that mediate inflammatory diseases affecting mucosal regions of the intestine, skin, and lungs. Read More

Date: 5/1/2007
LIGOCYTE PHARMACEUTICALS PRESENTS DATA SHOWING HETEROSUBTYPIC PROTECTION AGAINST INFLUENZA CHALLENGE WITH VIRUS-LIKE PARTICLE IMMUNIZATION
SOURCE: LigoCyte Pharmaceuticals, Inc.
Bozeman, Montana – May 1, 2007 – LigoCyte Pharmaceuticals presented preclinical data today showing that immunization with their influenza virus-like particles (VLPs) induced heterosubtypic protection in a virus challenge study. The company’s data were presented by Dr. Joel Haynes, LigoCyte’s senior director of vaccine development, at the Tenth Annual Conference on Vaccine Research sponsored by the National Foundation of Infectious Diseases in Baltimore. Read More

Date: 4/18/2007
LIGOCYTE PHARMACEUTICALS WINS SMALL BUSINESS OF THE YEAR AWARD
SOURCE: LigoCyte Pharmaceuticals & Prospera Business Network
Bozeman, Montana, April 18, 2007 – The U.S. Small Business Administration (SBA) announced today that the senior management team of Bozeman-based LigoCyte Pharmaceuticals, Inc. has been named the Small Business Administration’s 2007 Montana Small Business Persons of the Year. The LigoCyte senior team includes: Donald Beeman, Robert Goodwin, Charles Richardson and Robert Bargatze. As the Montana winner, LigoCyte will now advance to the national award category with finalists to be announced during Small Business Week in Washington, D.C. April 23-24, 2007. Read More

Date: 4/3/2007
LIGOCYTE PHARMACEUTICALS INITIATES U.S. CLINICAL TRIAL OF NOROVIRUS VACCINE
SOURCE: LigoCyte Pharmaceuticals, Inc.
Bozeman, Montana – April 3, 2007 – LigoCyte Pharmaceuticals, Inc. announced today that it has initiated the Phase I clinical trial of its investigational Norovirus vaccine at the University of Maryland Medical Center. The study will assess safety and immunogenicity of LigoCyte’s intranasally-delivered, dry powder vaccine in healthy adults. Read More